No Data
No Data
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)
We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth
Zura Bio Highlights Strategic Goals and Clinical Advances
Analysts Offer Insights on Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP), Ionis Pharmaceuticals (IONS) and Zura Bio (ZURA)
Cautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive Risks
Express News | HC Wainwright & Co. Reiterates Neutral on Zura Bio, Maintains $5 Price Target